Jefferies Sticks to Its Buy Rating for Neurocrine (NBIX)

Jefferies analyst Akash Tewari maintained a Buy rating on Neurocrine (NBIX – Research Report) yesterday and set a price target of $182.00. The company’s shares closed yesterday at $140.09.

Tewari covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Eli Lilly & Co, and Neurocrine. According to TipRanks, Tewari has an average return of 17.4% and a 57.06% success rate on recommended stocks.

In addition to Jefferies, Neurocrine also received a Buy from Oppenheimer’s Jay Olson in a report issued today. However, yesterday, Needham maintained a Hold rating on Neurocrine (NASDAQ: NBIX).

Based on Neurocrine’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $515.2 million and a net profit of $147.7 million. In comparison, last year the company earned a revenue of $412 million and had a net profit of $89 million

Based on the recent corporate insider activity of 78 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NBIX in relation to earlier this year. Most recently, in February 2024, Kevin Charles Gorman, the CEO of NBIX bought 5,090.00 shares for a total of $199,951.10.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Neurocrine (NBIX) Company Description:

Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.